Core B: Genome Engineering Core
Core B: Genome Engineering Core
批准号:
9891734
负责人:
Frederic D Bushman
金额:
$16.2万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-05-15 至 2025-04-30
关键词:
Adverse eventAliquotBehaviorCategoriesCell physiologyCellsChromosomal translocationCleaved cellClinicalClonal ExpansionClustered Regularly Interspaced Short Palindromic RepeatsComplexDNADataEventEvolutionFrequenciesGene therapy trialGene-ModifiedGenesGeneticGenetic TranscriptionGenomeGenome engineeringGenomicsGrowthHIVHIV-1HMGA2 geneHumanHuman GenomeImmunotherapyInfusion proceduresInsertional MutagenesisLentivirus VectorMethodsModificationMolecularMonitorNatureOutcomePathway interactionsPatientsProceduresProtocols documentationReagentRecurrenceSafetySiteSpecificityT-Cell ProliferationT-LymphocyteTechnologyTherapeutic EffectTimebasebeta Thalassemiacell growthcellular transductionclinical efficacydesignengineered T cellsexperienceexperimental studygene therapygenotoxicityhuman subjectimprovedintegration sitelentiviral integrationnucleasesafety assessmenttargeted nucleasestherapeutic cloningvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract Core B. Quantifying outcomes of genome modification
Core B will track the nature and consequences of genome modifications carried out in
Projects 1, 3 and 4, and use these data to design improved reagents for CART genome
modification. Core B will analyze several types of genome modification as dictated by
the needs of each project. Integration of lentiviral vectors necessarily disrupts the host
cell locus at the site of integration. We and others have found that insertional
mutagenesis by vectors used to deliver CARs can be associated with altered cell
growth, which has resulted in clinical adverse events, but also clinically favorable clonal
expansions that have bolstered therapeutic effects. The core will use these data to
identify genes and pathways to manipulate to optimize CART expansion and
persistence. Vector integration also marks each transduced cell uniquely, allowing
tracing of the partitioning of descendant cells, information useful in tracking outcomes
and understanding mechanisms of possible adverse events. Cleavage of the host
genome using targeted nucleases is also an effective means of achieving genome
modification; however, off-target cleavage and associated deletions are safety
concerns. The core will monitor off-target cleavage using our iGUIDE technology.
Lastly, in protocols where multiple sgRNA/CAS9 complexes cleave multiple targets in a
single cell, nuclease cleavage at multiple sites can result in rejoining of DNA ends in a
“swapped” fashion, causing chromosomal translocations. Core B will monitor molecular
outcomes in each of these categories to allow optimization of reagents, assessment of
safety, and scoring of cell function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core B. Genomics and Bioinformatics Core
-
批准号:10625575
-
项目类别:
-
资助金额:$16.78万
-
财政年份:2023
-
负责人:Frederic D Bushman
-
依托单位:
mVACS--mRNA Vaccines for C. difficile Suppression
-
批准号:10625573
-
项目类别:
-
资助金额:$153.0万
-
财政年份:2023
-
负责人:Frederic D Bushman
-
依托单位:
Preserving Genome Integrity In AAV-Mediated Gene Therapy
-
批准号:10338480
-
项目类别:
-
资助金额:$63.15万
-
财政年份:2022
-
负责人:Frederic D Bushman
-
依托单位:
Preserving Genome Integrity In AAV-Mediated Gene Therapy
-
批准号:10558679
-
项目类别:
-
资助金额:$64.52万
-
财政年份:2022
-
负责人:Frederic D Bushman
-
依托单位:
Core B: Genome Engineering Core
-
批准号:10450647
-
项目类别:
-
资助金额:$16.65万
-
财政年份:2020
-
负责人:Frederic D Bushman
-
依托单位:
Core B: Genome Engineering Core
-
批准号:10617345
-
项目类别:
-
资助金额:$16.03万
-
财政年份:2020
-
负责人:Frederic D Bushman
-
依托单位:
Core B: Genome Engineering Core
-
批准号:10165493
-
项目类别:
-
资助金额:$16.17万
-
财政年份:2020
-
负责人:Frederic D Bushman
-
依托单位:
Linking insertional mutagenesis and cell function to improve CAR T cell therapy
-
批准号:10398224
-
项目类别:
-
资助金额:$60.03万
-
财政年份:2019
-
负责人:Frederic D Bushman
-
依托单位:
Linking insertional mutagenesis and cell function to improve CAR T cell therapy
-
批准号:10158019
-
项目类别:
-
资助金额:$62.11万
-
财政年份:2019
-
负责人:Frederic D Bushman
-
依托单位:
Linking insertional mutagenesis and cell function to improve CAR T cell therapy
-
批准号:10640072
-
项目类别:
-
资助金额:$59.21万
-
财政年份:2019
-
负责人:Frederic D Bushman
-
依托单位:
The Lung DNA Virome in Health and Disease
-
批准号:9926300
-
项目类别:
-
资助金额:$74.96万
-
财政年份:2017
-
负责人:Frederic D Bushman
-
依托单位:
The Lung DNA Virome in Health and Disease
-
批准号:9303685
-
项目类别:
-
资助金额:$27.27万
-
财政年份:2017
-
负责人:Frederic D Bushman
-
依托单位:
Optimization HIV Inhibition by Allosteric Integrase Inhibitors
-
批准号:10077786
-
项目类别:
-
资助金额:$43.43万
-
财政年份:2017
-
负责人:Frederic D Bushman
-
依托单位:
The Lung DNA Virome in Health and Disease
-
批准号:9475867
-
项目类别:
-
资助金额:$26.95万
-
财政年份:2017
-
负责人:Frederic D Bushman
-
依托单位:
Lung Transplant Microbiome and Chronic Allograft Dysfunction
-
批准号:9066196
-
项目类别:
-
资助金额:$72.7万
-
财政年份:2013
-
负责人:Frederic D Bushman
-
依托单位:
Lung Transplant Microbiome and Chronic Allograft Dysfunction
-
批准号:8665468
-
项目类别:
-
资助金额:$73.69万
-
财政年份:2013
-
负责人:Frederic D Bushman
-
依托单位:
Lung Transplant Microbiome and Chronic Allograft Dysfunction
-
批准号:8847785
-
项目类别:
-
资助金额:$72.97万
-
财政年份:2013
-
负责人:Frederic D Bushman
-
依托单位:
Lung Transplant Microbiome and Chronic Allograft Dysfunction
-
批准号:8505677
-
项目类别:
-
资助金额:$74.29万
-
财政年份:2013
-
负责人:Frederic D Bushman
-
依托单位:
Inhibition of DNA modifying enzymes of category A-C agents
-
批准号:8233378
-
项目类别:
-
资助金额:$30.52万
-
财政年份:2011
-
负责人:Frederic D Bushman
-
依托单位:
THE MACAQUE GUT MICROBIOME IN HEALTH, LENTIVIRAL INFECTION AND IBD
-
批准号:7958653
-
项目类别:
-
资助金额:$6.27万
-
财政年份:2009
-
负责人:Frederic D Bushman
-
依托单位:
海外基金